Filing Details
- Accession Number:
- 0001179110-18-002591
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-02-22 16:25:38
- Reporting Period:
- 2018-02-20
- Accepted Time:
- 2018-02-22 16:25:38
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1578845 | Allergan Plc | AGN | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1269428 | M Matthew Walsh | Clonshaugh Business And Technology Park Dublin L2 D17 E400 | Evp, Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, Par Value $0.0001 | Acquisiton | 2018-02-20 | 13,076 | $160.59 | 13,076 | No | 4 | A | Direct | |
| Ordinary Shares, Par Value $0.0001 | Acquisiton | 2018-02-20 | 9,340 | $160.59 | 22,416 | No | 4 | A | Direct | |
| Ordinary Shares, Par Value $0.0001 | Acquisiton | 2018-02-21 | 2,000 | $160.94 | 24,416 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | A | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Performance-Based Restricted Stock Unit | Acquisiton | 2018-02-20 | 28,021 | $0.00 | 28,021 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 28,021 | No | 4 | A | Direct |
Footnotes
- The reported securities are restricted share units ("RSUs"), each of which represents a right to receive one ordinary share of Allergan plc. The RSUs were issued pursuant to the provisions of the 2013 Incentive Award Plan of Allergan plc and shall vest 25% on each of February 20, 2019, February 20, 2020, February 20, 2021 and February 20, 2022.
- Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.
- The reported securities are RSUs, each of which represents a right to receive one ordinary share of Allergan plc. The RSUs were issued pursuant to the provisions of the 2013 Incentive Award Plan of Allergan plc and shall vest 20% on each of February 20, 2019, February 20, 2020, February 20, 2021, February 20, 2022 and February 20, 2023.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.80 to $160.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- Represents performance-based restricted share units ("PSUs") which will vest as to 50% of the total grant on each of December 31, 2020 and December 31, 2021, subject to the achievement by the Issuer of certain performance criteria. Each PSU represents a contingent right to receive a number of ordinary shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person.
Billionaire Hedge Funds
